Ribavirin is a potential teratogen. Precautions must be taken to prevent teratogenic injury in a fetus born to a woman exposed to ribavirin directly or indirectly.
If a male or female in a heterosexual relationship is taking ribavirin, then the partners should:
(1) practice at least 2 forms of reliable contraception.
(2) the woman should have a negative pregnancy test before starting therapy and while being treated
(3) contraception should be continued for at least 6 months after discontinuation of ribavirin therapy (15 half-lives).
In addition:
(1) Females of reproductive age working in the pharmaceutical industry should not be exposed to ribavirin during its production or packaging.
(2) Female health care workers of reproductive age should not to be exposed to ribavirin during its preparation or administration to patients.
To read more or access our algorithms and calculators, please log in or register.
